MainFirst Bank AG (a Stifel Company)
Dr. Marcus Wieprecht
Fon: +49 (0) 69 78808 221
60596 Frankfurt am Main
|24 March 2021
|Good pipeline progress not reflected in 4SC’s current valuation
|12 August 2020
|Q2 update: gradually going back to normal
|2 March 2020
|Initiating Coverage with a Buy rating:
Emerging epigenetic cancer drug pipeline
Any opinions, estimates or forecasts made by these analysts on the performance of 4SC AG are not opinions, forecasts or predictions of 4SC AG or its management. By providing the list above, 4SC AG does not imply its endorsement of or concurrence with such information, conclusions or recommendations.
The list has been drawn up to the best of our knowledge. 4SC AG cannot give any assurance that the list represents a full overview of all analyst reports available on the market. This list may not be complete and may change from time to time. We update the list periodically, but undertake no obligation to do so.